People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Personalis, Inc. | — | Biotechnology | Series B | $68.9M | $485.2M | 2011 |
| Attlee, Inc. | — | Other | Pre-Seed | $250K | $5.8M | 2009 |
Sue Siegel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sue Siegel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan MacQuitty | 1 | 7 |
| Rowan Chapman | 1 | 7 |
| Chris Schaepe | 1 | 6 |
| JON FEIBER | 1 | 5 |
| Andrew Chung | 1 | 4 |
| Jonathan Turner | 1 | 3 |
| Ken Ludlum | 1 | 3 |
| Patrick Balthrop | 1 | 3 |
| John West | 1 | 2 |
| Vincent Miles | 1 | 2 |
| Adrian Dollard | 1 | 1 |
| Carol Tillis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.